Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc33007575    free
PDF from PMC    free
html from PMC    free
PDF vom PMID33007575  :  Publisher

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • An in-silico evaluation of COVID-19 main protease with clinically approved drugs #MMPMID33007575
  • Tachoua W; Kabrine M; Mushtaq M; Ul-Haq Z
  • J Mol Graph Model 2020[Dec]; 101 (ä): 107758 PMID33007575show ga
  • A novel strain of coronavirus, namely, SARS-CoV-2 identified in Wuhan city of China in December 2019, continues to spread at a rapid rate worldwide. There are no specific therapies available and investigations regarding the treatment of this disease are still lacking. In order to identify a novel potent inhibitor, we performed blind docking studies on the main virus protease M(pro) with eight approved drugs belonging to four pharmacological classes such as: anti-malarial, anti-bacterial, anti-infective and anti-histamine. Among the eight studied compounds, Lymecycline and Mizolastine appear as potential inhibitors of this protease. When docked against M(pro) crystal structure, these two compounds revealed a minimum binding energy of -8.87 and -8.71 kcal/mol with 168 and 256 binding modes detected in the binding substrate pocket, respectively. Further, to study the interaction mechanism and conformational dynamics of protein-ligand complexes, Molecular dynamic simulation and MM/PBSA binding free calculations were performed. Our results showed that both Lymecycline and Mizolastine bind in the active site. And exhibited good binding affinities towards target protein. Moreover, the ADMET analysis also indicated drug-likeness properties. Thus it is suggested that the identified compounds can inhibit Chymotrypsin-like protease (3CL(pro)) of SARS-CoV-2.
  • |Animals[MESH]
  • |Anti-Bacterial Agents/chemistry[MESH]
  • |Antiviral Agents/chemistry/pharmacokinetics/pharmacology[MESH]
  • |Binding Sites[MESH]
  • |Computer Simulation[MESH]
  • |Coronavirus 3C Proteases[MESH]
  • |Cysteine Endopeptidases/*chemistry/metabolism[MESH]
  • |Databases, Pharmaceutical[MESH]
  • |Drug Approval[MESH]
  • |Drug Repositioning[MESH]
  • |Histamine Antagonists/chemistry[MESH]
  • |Molecular Docking Simulation[MESH]
  • |Molecular Dynamics Simulation[MESH]
  • |Protease Inhibitors/*chemistry/pharmacokinetics/*pharmacology[MESH]
  • |Viral Nonstructural Proteins/*antagonists & inhibitors/*chemistry/metabolism[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    107758 ä.101 2020